Enlivex Ltd
1BT
Company Profile
Business description
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Contact
14 Einstein Street
Weizmann Science Park
Ness Ziona7403618
ISRT: +972 86328500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
34
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,068.10 | 46.30 | 0.51% |
| CAC 40 | 8,421.14 | 46.84 | -0.55% |
| DAX 40 | 24,985.82 | 40.98 | -0.16% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,363.27 | 36.43 | -0.35% |
| HKSE | 23,450.46 | 474.35 | -1.98% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 72,533.14 | 1,283.08 | 1.80% |
| NZX 50 Index | 13,519.22 | 23.59 | 0.17% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,850.30 | 48.40 | 0.55% |
| SSE Composite Index | 4,093.78 | 3.30 | 0.08% |